Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer

Urology

Volumn 48, Issue 6 SUPPL., 1996, Pages 4-9

  Pearson, Jay D ^c   Luderer, Albert A ^d   Metter, E Jeffrey ^b   Partin, Alan W ^a   Chan, Daniel W ^a   Fozard, James L ^b   Carter, H Ballentine ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Dianon Systems   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; FALSE POSITIVE REACTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0030476722     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00603-6     Document Type: Article

References (11)

1. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, and Kidd DD: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143: 1146-1152, 1990.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
3. Gann PH, Hennekens CH, and Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273: 289-294, 1995.
4. Christennson A, Laurell CB, and Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763, 1990.
5. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, and Alfthan O: A complex between prostate-specific antigen and alphal-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
6. Lilja H, Christensson A, Dahlen U, Matikainen M, Nilsson O, Petterson K, and Lovgren T: Prostate-specific antigen in human serum occurs predominantly in complex with alphal-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
7. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TI, Wolfert RL, Lilja H, and Oesterling JE: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45: 729-744, 1995.
8. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RBC. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
9. Chen Y-T, Luderer AA, Thiel RP, Carlson G, Cuny CL, and Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 47: 518-524, 1996.
10. Shock NW, Greulich RC, Andres R, Arenberg D, Costa PT, Jr, Lakatta EG, and Tobin JD: Normal Human Aging: The Baltimore Longitudinal Study of Aging. Washington, DC: US GPO (NIH publication no. 84-2450), 1984.
11. Lindstrom MJ, and Bates DM: Newton-Raphson and EM algorithms for linear mixed-effects models for repeated-measures data. J Am Stat Assoc 83: 1014-1022, 1988.